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A B S T R A C T
In this prospective study we wanted to report our experience and to evaluate the effiacacy and safety of Ex-press
Mini-Glaucoma Shunt implantation under a superficial scleral flap, as a newly and improved surgical technology in a
treatment of POAG(Primary open-angle glaucoma) and refractory glaucoma. 44 eyes (35 patients) underwent an implan-
tation of Ex-Press Mini Glaucoma Shunt. We had 21 patiens with POAG (60%) and 14 patients with PEXG-pseudo-
exfoliation glaucoma (40%). The follow-up period was 8.62+7.48 months (range 2–22 months). Main outcome measures
included postoperative IOP control, postoperative medications and early postoperative complications. The IOP was mea-
sured in the following postoperative time-points of 1 day, 1 week, 1, 3, 6, 9 and 12 months. The mean IOP values 1 year
postoperatively were reduced for 52.8% compared to preoperative values and the use of medications were reduced for
77%. We had complications like postoperative hypotony (3.5%), choroidal ablation (7%), intraocular hemorrhage (3.5%)
and postoperative shunt closure (3.5%). The Ex PRESSMini Glaucoma Shunt implanted under a superficial scleral flap
is relatively safe and effective surgical procedure and provides satisfactory IOP control and medication reduction. How-
ever, device related complications remain still a problem.
Abbreviations: POAG – Primary open-angle glaucoma, PEXG – Pseudoexfoliation glaucoma, IOP – Intraocular
pressure
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Introduction
Glaucoma is the second cause of blindness in the
world1. It is defined as a group of diseases that are char-
acterized by the common feature of progressive optic
neuropathies (the open –angle glaucoma) or feature of
occludable angle drainage in the anterior chamber (the
closed-angle glaucoma). The innermost cases of these pa-
tients have the open-angle glaucoma (OAG). The therapy
of these type of glaucoma can be medical with antiglau-
comatous eye drops or surgerical treatment. As the step
between two therapies, laser treatment can be used (Ar-
gon laser trabeculoplasty or Selective laser trabeculo-
plasty)2–5.
Glaucoma filtration surgery is usually performed on
patients who have uncontrolled intraoculare pressure
despite of all medical treatment or failed laser trabecu-
loplasty.
In novel time, in a surgical treatment of open angle
glaucoma (OAG), an implant named Ex-press Mini-Glau-
coma Shunt is used6.
It is well known surgical technique and worlwide
available for almost a decade. The new developments in
ophtalmic surgery are primarly focused on smaller inci-
sions and effective control of IOP and therefore less com-
plications associated with trabeculectomies or traditio-
nal glaucoma drainage implants7.
In this prospective study we wanted to report our ex-
perience and to evaluate the effiacacy and safety of
Ex-press Mini-Glaucoma Shunt implantation under a su-
perficial scleral flap, as a newly and improved surgical
technology in a treatment of POAG and refractory glau-
coma.
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Materials and Methods
We prospectively analysied 44 eyes who underwent to
Ex-PRESS Mini Glaucoma Shunt implantation under a
superficial scleral flap. We studied 34 patients: 16 males
(47.71%) and 19 females (54.28%). We had 21 patiens
with POAG (60%) and 14 patients with PEXG-pseudo-
exfoliation glaucoma (40%). Patients were excluded if
they had angle closure glaucoma, normal tension glau-
coma, secondary glaucoma, uveitis or cataract. Also they
were excluded if they had previous ocular surgery other
than filtering surgery or uncomplicated cataract surgery.
The follow-up period was 8. 62+7.48 months (range 2–22
months). The mean age of the studied population was
63.68+7.69 years. The primary outcome measures were
mean IOP, postoperative medication use and early post-
operative complications and those were evaluated and
calculated in comparision to preoperative outcomes. The
IOP was measured in the following postoperative time-
-points of 1 day, 1 week, 1, 3, 6, 9 and 12 months. All pa-
tients received the same ophthalmic examination preop-
eratively and at intervals postoperatively. All operations
were done by the same surgeon and under same sugical
procedure.
Results
One year postoperatively, mean IOP in all patients de-
creased from 31.15±6.28 to 14.70±4.74 mmHg (p<0.001).
(Figure 1.). Mean number of medications was reduced
from 3.1±0.70 preoperatively to 0.70±0.79 postoperati-
vely. The successful procedure was defined as those in
which postoperative IOP was > 5mmHg or <18 mmHg
without the use of antiglaucomamedications. A review of
the early postoperative complications related to Ex-Press
Mini Glaucoma Shunt revealed 1 case of hypotony (IOP
<5mmHg – 3.5%), 2 cases of hypotony with choroidal de-
tachment (7%), 1 case of excesive intraocular haemor-
rhage 24 hours postoperatively (3.5%) and 1 one case of
postoperative shunt closure (3.5%) which was success-
fully solved by needling revision procedures.
Discussion
The open-angle glaucoma is a progressive optic neu-
ropathy resulting in a loss of retinal ganglion cells and
therefore a progressive damage of a visual field8. The pri-
mary goal of glaucoma treatment is reducing intraocular
pressure by means of medications or surgical options9.
Traditional glaucoma surgery treatment as trabeculec-
tomy has been related to many complications 10. The
novel and alternative procedure is implantation of the
Ex-press mini glaucoma shunt under scleral flap11–13.
The device is a small stainless steel, nonvalvuled flow-re-
stricting device developed as less invasive surgical proce-
dure. As we noticed before, today the expresss mini glau-
coma shunt is recomended as the first surgical option, as
well as the second surgical option in cases when the
clasic trabeculoplasty did not give expected results.
Several studies investigated the efficacy and safety of
Ex-press mini glaucoma shunt compared to standard
trabeculectomy. All of them demonstrated significant
higher success rates compared to standard procedure to
lower intraocular pressure in the treatment of open-an-
gle glaucoma, fewer prescriptions for IOP medications,
higher responder rates and also showed significant lon-
ger time without need for medications. However, Ex-
-Press device is not without complications such as early
hypotony, but it ensures greater predictability with less
complications in general, like inflammation, hypotony
and also provides more rapid visual recovery. It well
known that the Ex-Press also has a wider range of indica-
tions than trabeculectomy. In our study the mean IOP
values and the number of medications for all patients
were significantly decreased from the preoperative mea-
sures at all intervals. The mean IOP values 1 year post-
operatively were reduced for 52.8% compared to preoper-
ative values and the use of medications were reduced for
77% what is in accordance with so far published stu-
dies10–13. We had complications like postoperative hypo-
tony (3.5%), choroidal ablation (7%), excessive intraocu-
lar hemorrhage (3.5%) and postoperative shunt closure
(3.5%). None of the patient developed a conjuctival ero-
sion. All early postoperative complications were success-
fully resolved.
In conclusion, our study showed that Ex-Press Mini
Glaucoma shunt implantation under partial thickness
scleral flap is safe and effective procedure in a treatment
of an open-angle glaucoma and refractery glaucoma what
confirmed the results presented in previous studies10–13.
This promising and relatively new device provides
satisfactory IOP control, medication reduction, higher
responder rates and low rate of device related complica-
tions.
However, on the basis of review of the publised litera-
ture and studies, the longer follow up period is needed to
summarized all advanteges and disadvantages of this
novel glaucoma surgical technique.
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Fig. 1. Reduction of the mean IOP after Ex-Press Mini Glaucoma
Shunt implantation during following time-points postoperative-
ly. (* p0,05, student t-test).
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KLINI^KO ISKUSTVO SA »EX-PRESS MINI GLAUCOMA SHUNT«
S A @ E T A K
U ovoj prospektivnoj studiji smo htjeli prikazati na{a iskustva sa Ex- Press Mini Glaucoma Shunt-om kao i evalui-
rati u~inkovitost i sigurnost ove nove i pobolj{ane kirur{ke tehnike u tretmanu primarnog glaukoma otvorenog kuta i
refraktivnog glaukoma. 44 oka su podvrgnuta ovom kirur{kom postupku. Imali smo 21 pacijenta s dijagnozom primar-
nog glaukoma otvorenog kuta te 14 pacijenata s dijagnozom pseudoeksfolijativnog glaukoma. Vremenski period pra}e-
nja pacijenata je bio 8,62+7,48 mjeseci (raspon 2–22 mjeseci). Glavna postoperativna mjerenja su bili IOT (intraoku-
larni tlak), potreba za medikamentoznom terapijom te rane postoperativne komplikacije. IOT je mjeren u periodima od
1 dana, 1 tjedna te 1, 3, 6, 9 i 12 mjeseci nakon operacije. Srednja vrijednost IOT se nakon 1 godine smanjila za 52,8% u
odnosu na preoperativne vrijednosti,dok se potreba za medikacijom smanjila za ~ak 77% {to je u skladu s dosada objav-
ljenim studijama. Od ranih postoperativnih komplikacija imali smo 1 pacijenta s postoperativnom hipotonijom (3,5%),
2 pacijenta s ablacijom `ilnice (7%), 1 pacijenta s intraokularnim krvarenjem (3,5%) te 1 pacijenta s postoperativnom
obstrukcijom shunt-a (3,5%). Na osnovu navedenih podataka mo`emo zaklju~iti da je implantacija Ex-Press Mini Glau-
coma Shunt-a ispod skleralnog flap-a sigurna i u~inkovita kirur{ka metoda koja pru`a zadovoljavaju}u kontrolu IOT-a
te smanjenu potrebu za medikacijom postoperativno, kao i nisku stopu ranih postoperativnih komplikacija povezanih
sa implantacijom samog shunt-a.
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